Post hoc analysis of a phase 3 trial in 917 adults with MASH and F2–F3 fibrosis: at 52 weeks MASH resolution was 25.7% (resmetirom 80 mg) and 29.9% (100 mg) vs 9.5% placebo; fibrosis improvement 26.5% and 28.9% vs 17.3%. No new safety signals.
Secondary analysisn = 917
Mironova et al. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset